FDA Approval, page-148

First 148 Last

Share
Profile

Follow
Cotton2103

1,377 Posts.

371

30/06/22

13:07

Post #: 62295505
Share

Originally posted by Investau: ↑

I know there's been a lot of speculation about A2M Management asleep at the wheel, too busy lunching etc and I know it's crazy but lets just imagine for a moment they are acting in the best interests of advancing the company and growing revenue opportunities (crazy I know but hear me out):

I've been looking further into US consumption and purchasing of infant formula and, in particular, the WIC (Women, Infants, Children) programme. Firstly, a few stats I've been able to find as well as some educated assumptions:

- According to the USDA Economic Research Service, 60-70% of all infant formula purchased in the US is purchased through WIC.
- Through fiercely competitive bidding and exclusive rights grants, WIC buys from manufacturers at steeply discounted prices
- WIC claims $1.5-2Bn of savings and spends around $1Bn on formula implying an average discount from manufacturers of around 60-65%
- In Australia, a $35 tin of formula sold at a 25% margin assumes a fully loaded (incl. transport, marketing, wages, rent etc) cost per tin of $30
- If WIC is purchasing at 65% discount to retail this equates to around $10-12 per tin.
- Every tin sold to WIC invites a loss of $18-$20

We can speculate on US Govt funded shipping etc but that won't really impact the reality above and it's more likely than not that the long held monopolies in the US will resume their power after November.

Bubs has jumped on the opportunity to provide formula to the US and all praise to them. There is little doubt they are losing a fair bit of money by doing so but they are essentially investing in marketing to raise their brand profile and that works for them. They may get some advantage from selling outside of WIC in the longer term but I'd put a low percentage chance on that.

A2 Milk is in a very different position to Bubs and I would rather they focus on driving revenue and increasing margin in the most appropriate long term channels. I'm not saying they shouldn't entertain selling formula in the US but only if the deal is right and it's a long term play.

Finally, a lot of people are saying management should communicate more - I'd personally love to hear more from them but for what benefit? So I can profit from short term trading and speculation? That's not their role, they are there to drive long term growth in the business and they have clearly stated when they'll provide updates. Any commentary outside of that just invites complaints from those who feel they were misled.

We will no doubt see ups and downs over the remainder of the year and beyond but I have a lot of faith (and investment) in the long term growth of this company. The fundamentals impress me and there are some good contributions on these threads with real data, charts and commentary, everything else is just distracting noise.

GLTAH

Expand

Has Bubs ever turned a profit?

A2M Price at posting: $4.47 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

PME

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

BM8

Battery Age Minerals gets set to capitalise on critical mineral demand

ASX Market Update: Index pulls back from record highs | October 16, 2024

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

KAU

Kaiser Reef reports new A1 untapped gold zone – flags move past 'remnant mining'

There are more pages in this discussion • 171 more messages in this thread...

First 148 Last

Add A2M (ASX) to my watchlist

(20min delay)
Last $6.14		Change -0.220(3.46%)		Mkt cap ! $4.478B

Open	High	Low	Value	Volume
$6.30	$6.33	$6.12	$11.33M	1.830M

Buyers (Bids)

No.	Vol.	Price($)
5	18357	$6.75

Sellers (Offers)

Price($)	Vol.	No.
$5.53	142660	3

View Market Depth

No.	Vol.	Price($)
4	2398	6.130
8	16708	6.120
10	32925	6.110
16	50514	6.100
9	12869	6.090

Price($)	Vol.	No.
6.140	12504	11
6.150	7561	8
6.160	22909	11
6.170	24730	11
6.180	15532	7

Last trade - 15.59pm 16/10/2024 (20 minute delay)

A2M (ASX) Chart

FDA Approval, page-148

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

Battery Age Minerals gets set to capitalise on critical mineral demand

ASX Market Update: Index pulls back from record highs | October 16, 2024

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Kaiser Reef reports new A1 untapped gold zone – flags move past 'remnant mining'

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

FDA Approval, page-148

Top Stories

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

Battery Age Minerals gets set to capitalise on critical mineral demand

ASX Market Update: Index pulls back from record highs | October 16, 2024

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Kaiser Reef reports new A1 untapped gold zone – flags move past 'remnant mining'

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News